Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449 [PMID: 33024395 DOI: 10.3748/wjg.v26.i36.5437]
Corresponding Author of This Article
Anuj Bohra, BMed, Doctor, Research Fellow, Department of Gastroenterology, Eastern Health, 3 West, 8 Arnold Street, Box Hill 3128, Victoria, Australia. anujbohra@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Univariable and multivariable logistic regression analyses depicting factors potentially associated with increased likelihood of infliximab infusion reaction/s with a rapid infusion protocol in this cohort (n = 129)
Variable
Univariable odds ratio (95%CI)
P value
Multivariable odds ratio (95%CI)
P value
Lower BMI (< 22 kg/m2)
2.0 (0.7, 6.0)
0.15
5.3 (1.3, 21.6)
0.02
Presence of ≥ 1 extra intestinal manifestation
4.0 (1.4, 11.8)
0.01
8.8 (2.3, 33.5)
< 0.01
Disease duration ≥ 3 yr
4.8 (1.1, 20.5)
0.01
6.1 (1.1, 35.1)
0.04
Previous infliximab exposure (≥ 1 dose)
5.8 (1.2, 27.2)
0.02
Previous other biologic exposure (any other agent)
18.6 (1.6, 218.0)
0.03
34.9 (2.1, 576.7)
0.01
Previous break off infliximab (≥ 3 m)
5.1 (1.3, 19.4)
0.03
4.8 (0.8, 28.4)
0.08
Concurrent immunomodulator (any)
0.1 (0.01, 1.1)
0.06
Concurrent thiopurine
0.3 (0.1, 1.001)
0.06
Previous adverse drug reaction (any)
2.2 (0.7, 6.7)
0.12
Known psychiatric comorbidity
2.4 (0.8, 6.7)
0.10
Pre-medication used
0.5 (0.3, 1.00)
0.08
Table 4 Characteristics of home-based vs infusion centre-based rapid protocol groups
Variable
Home based rapid infusion group, n (%)
Infusion centre based rapid infusion group, n (%)
P value
Total patients/infusions
32 / 405
97/1067
-
Male (%)
18 (56.2)
37 (38.1)
0.10
Age (median, range)
36 (18, 79)
42(16, 86)
0.05
BMI > 30
7 (21.9)
24 (24.7)
0.82
Smoker
6 (18.8)
20 (20.6)
1.00
Disease type
CD
26 (81.2)
88 (90.7)
0.20
UC
6 (18.8)
8 (8.2)
0.11
Indeterminate
0 (0)
1 (1.0)
1.00
Extra-intestinal manifestations
9 (28.1)
20 (20.6)
0.46
Psychiatric co-morbidity
10 (31.2)
35 (36.1)
0.67
ADRs (any severity)
0 (0.0%)
8 (8.2)
0.20
Citation: Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449